[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1997


Author Affiliations

Baltimore, Md

Arch Ophthalmol. 1997;115(6):785-786. doi:10.1001/archopht.1997.01100150787016

Cytomegalovirus (CMV) retinitis is the most common intraocular opportunistic infection in patients with the acquired immunodeficiency syndrome.1 Studies have suggested that CMV retinitis will develop in approximately 25% to 35% of patients with the acquired immunodeficiency syndrome sometime between the diagnosis of acquired immunodeficiency syndrome and death.1,2 Without treatment, CMV retinitis spreads throughout the retina resulting in total retinal destruction and blindness.3 Drugs for CMV retinitis that have been approved by the Food and Drug Administration as of April 1996 include intravenous ganciclovir,3-6 intravenous foscarnet,6,7 oral ganciclovir,8,9 the ganciclovir intraocular device,10 and intravenous cidofovir.11,12, Intravenous ganciclovir and foscarnet have been demonstrated to be effective for the treatment of CMV retinitis3-7 but require the placement of a permanent indwelling central venous catheter for the administration of daily intravenous infusions. Central venous catheters may adversely affect quality of life and are associated with

First Page Preview View Large
First page PDF preview
First page PDF preview